Comparison of fetal safety of vaginal Misoprostol tablet and Dinoprostone gel for induction of labor: An open‐label randomized control trial
Journal of Obstetrics and Gynaecology Research · 2023
DOI: 10.1111/jog.15737 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Ajanta Samanta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology and Obstetrics, Medical College, Kolkata, India. Hauptthemen laut MEDLINE: Misoprostol, Oxytocics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: MRU-Multidisciplinary Research Unit, Medical College, Kolkata.
Abstract (Originalsprache)
Aim
In modern obstetrics, need of labor induction is increasing along with increased caesarean deliveries. Major contributions for these operative deliveries are due to induction failure. This demands a potent labor‐inducing agent. Dinoprostone gel is an established method but having some drawbacks. Misoprostol could be an effective alternative to Dinoprostone, but its fetal safety is not yet well established. This study aimed to evaluate the fetal safety of vaginal Misoprostol tablet by measuring fetal heart rate changes during induction of labor.
Methods
This was a single‐center randomized controlled trial incorporating 140 term women, equally randomized to get either tablet Misoprostol or Dinoprostone gel. Fetal heart rate patterns were compared in both the groups by continuous cardiotocographic tracing. All the data were analyzed on an intention‐to‐treat basis.
Results
There were no statistically significant changes in fetal heart rate pattern in both Misoprostol and Dinoprostone groups. Vaginal deliveries were statistically higher in Misoprostol group. Neonatal parameters like 1 min Appearance, Pulse, Grimace, Activity, and Respiration score and neonatal intensive care unit admission were comparable, and there was no significant difference in terms of major adverse events and side effects.
Conclusions
Misoprostol is a safe alternative to Dinoprostone gel for induction of labor and found to be more effective labor‐inducing agent. In the background of higher caesarean rate, vaginal Misoprostol can be a potential labor‐inducing agent especially in a resource poor setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecology and Obstetrics, Medical College, Kolkata, India.
- Department of Community Medicine, Medical College, Kolkata, India.
- Department of Cardiology, Medica Superspecialty Hospital, Kolkata, India.
ORCID-Profile: Ajanta Samanta
Förderung
- MRU-Multidisciplinary Research Unit, Medical College, Kolkata
Zitieren
APA
Samanta, A., Rakshit, B. M., Mistri, P. K., Chakraborty, A., Bag, T., Das, P., & Pande, A. (2023). Comparison of fetal safety of vaginal Misoprostol tablet and Dinoprostone gel for induction of labor: An open‐label randomized control trial. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15737
Vancouver
Samanta A, Rakshit BM, Mistri PK, Chakraborty A, Bag T, Das P, et al. Comparison of fetal safety of vaginal Misoprostol tablet and Dinoprostone gel for induction of labor: An open‐label randomized control trial. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15737
BibTeX
@article{Samanta2023,
author = {Samanta, Ajanta and Rakshit, Bibek Mohan and Mistri, Pallab Kumar and Chakraborty, Arup and Bag, Tarasankar and Das, Piyali and Pande, Arindam},
title = {Comparison of fetal safety of vaginal Misoprostol tablet and Dinoprostone gel for induction of labor: An open‐label randomized control trial},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2023},
doi = {10.1111/jog.15737}
}
EUVIMED